GlobeNewsWire
29 Sept 2025, 12:00 UTC · 51w ago
Verdict
Headline takes no side. We score LSTA +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The combination of certepetide with FOLFIRINOX achieved a 60% two-year overall survival rate and a 12-month median disease-free survival in resectable pancreatic cancer patients.
So whatEfficacy survival metrics are the most market-moving data for clinical-stage oncology firms, and a 60% two-year OS in a disease with a 13% five-year survival rate is highly significant.
More positive than 99% of claims this week
Tumor tissue analysis demonstrated certepetide transformed pancreatic tumors from 'immune-cold' to 'immune-hot' with enhanced immune cell infiltration and increased PD-1/PD-L1 expression.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 98% of claims this week
Among the 10 PDAC patients eligible for surgery, the combination therapy yielded a 50% R0 resection rate and a 70% pathologic partial response rate.
More positive than 98% of claims this week
The combination of certepetide with FOLFIRINOX was safe and feasible, with no serious adverse events attributed to certepetide.
More positive than 87% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company announced encouraging preliminary data from its Phase 1/2a trial for pancreatic cancer, showing promising survival and resection rates.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
8h ago
−36.0%
Price is moving against the score
$1.58 vs $2.47 close before publication (Sep 26) · not market-adjusted
LSTA chart →
